Compare ACADIA Pharmaceuticals Inc. (ACAD) vs DigitalOcean Holdings Inc (DOCN) Price & Performance
Price performance
Price movement over the last 24 hours
Key statistics
Key statistics
ACADIA Pharmaceuticals Inc. vs DigitalOcean Holdings Inc — how do they compare? ACADIA Pharmaceuticals Inc. trades at $25.76 (market cap $4.49B), while DigitalOcean Holdings Inc trades at $138.54 (market cap $14.30B). The key difference: DigitalOcean Holdings Inc is far larger — about 3.2× ACADIA Pharmaceuticals Inc.'s market cap. Which is the better fit depends on your goals.
| ACAD | DOCN | |
|---|---|---|
Market Cap | $4.49B | $14.30B |
Sector | Health | Technology |
52-Week High | $28.06 | $181.29 |
52-Week Low | $20.06 | $25.74 |
Enterprise Value | $3.69B | $14.86B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
ACAD trades at $26.20, up 0.89% today, with strong analyst consensus (70% buy ratings) and a $33.67 price target. Recent CHMP recommendation for Daybue in Europe (Business Wire, June 26, 2026) drove positive sentiment. The stock shows bullish technical signals with moving averages supporting upside, though RSI levels indicate overbought conditions. Fundamentally, revenue grew to $1.07B in 2025 with a robust net income margin of 34.3%, though Q1 2026 earnings missed expectations.
Outlook remains positive given commercial execution and pipeline catalysts like remlifanserin data, but risks include earnings volatility and regulatory dependencies. The stock offers growth potential in neuropsychiatry markets, balanced by execution risks in clinical trials and competitive pressures.
DigitalOcean (DOCN) trades at $137.12, up 5.37% today amid strong Q2 2026 preliminary results showing accelerated growth. The stock exhibits bearish technical signals but maintains robust fundamentals with consistent earnings beats, 58.49% gross margins, and 24.97% net income margins. Recent news highlights inclusion in the Russell 1000 Index and AI-driven cloud demand, with analyst consensus bullish at a $169.91 price target.
Outlook remains positive given AI-native cloud positioning and revenue growth, though high valuation ratios (P/E 57.62) and negative shareholder equity pose risks. Upside depends on execution of growth initiatives, while competition and debt levels warrant monitoring.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About ACADIA Pharmaceuticals Inc.
Acadia Pharmaceuticals is a biotechnology company that develops and commercializes biopharmaceutical products to address central nervous system disorders. The company aims to discover small molecule drugs that address disorders such as Parkinson's, Alzheimer's, and schizophrenia. Acadia also seeks to in-license or acquire complementary products and candidates. The company's patent applications claim proprietary technology, including novel methods of screening and chemical synthetic methods, novel drug targets, and novel compounds identified using its technology.
Read more on ACAD →About DigitalOcean Holdings Inc
DigitalOcean Holdings Inc is a cloud computing platform offering on-demand infrastructure and platform tools for developers, start-ups and small and medium-sized businesses. The customers use the platform for a wide range of cases, such as web and mobile applications, website hosting, e-commerce, media and gaming, personal web projects, and managed services, among many others. The group has a business presence in North America, Europe, Asia and other countries.
Read more on DOCN →
